Pharvaris N.V. (PHVS)
Pharvaris develops drug candidates for hereditary angioedema, a rare condition that causes episodes of severe swelling. It last closed at $31.28 on Nov 20, down 1.20% on the day. Over the last 12 months PHVS insiders bought $0 of stock on the open market and sold $33.0M, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From PHVS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Apr 2). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on PHVS
Technical AnalysisPrices may be delayed
The stock is 6% below its 20 day and 5% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 41). The nearest support is the Pivot at $31.23, and the nearest resistance the 200 day average at $31.46.
| RSI (14) | 40.78 | Middle of its range | Neutral |
| MACD | -0.13 | Below its signal line | Bearish |
| Stochastic | 11.7 | Near the bottom of its range | Oversold |
| ADX (14) | 16.8 | No clear trend | |
| Williams %R | -83.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -140.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −9.0% | Change over 10 sessions | Bearish |
| ATR (14) | $1.50 | Typical daily range, 4.8% of price |
| RSI (14) | 47.58 | Middle of its range | Neutral |
| MACD | 0.40 | Below its signal line | Bearish |
| Stochastic | 34.2 | Middle of its range | Neutral |
| ADX (14) | 26.8 | Trending up | |
| Williams %R | -76.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -71.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −17.7% | Change over 10 sessions | Bearish |
| ATR (14) | $3.40 | Typical daily range, 10.9% of price |
What happened before
See how PHVS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PHVS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options FlowPrices may be delayed
90DNo whale options trades in PHVS in the last 90 days.
PHVS Institutional Ownership
Full report →- ▲80 buying vs 47 selling
- ▲Shares held by funds +3.8%
- ▲Funds holding +10
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 135 | 125 | +8.0% |
| In funds' top 10 | 15 | 14 | +7.1% |
| Held by funds | – | – | – |
| New / increased | 22 / 58 | 23 / 47 | +14.3% |
| Reduced / sold out | 34 / 13 | 33 / 10 | +9.3% |
| Put/call ratio | 1.39 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
PHVS Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23 | Viviane MongesDirector | Sale | 11,969 | $33.05 | $396K |
| Sep 22 | Johannes Gerardus Christiaan Petrus SchikanDirector | Sale | 800 | $36.19 | $29K |
| Sep 21 | David W. NassifCFO / Clo | Sale | 6,000 | $36.47 | $219K |
| Sep 17 | Anne LesageChief Early Development | Sale | 20,000 | $38.27 | $765K |
| Sep 17 | Robert GlassmanDirector | Sale | 14,493 | $38.56 | $559K |
| Sep 17 | Elisabeth BjorkDirector | Sale | 52,500 | $37.89 | $2.0M |
From SEC Form 4 filings by PHVS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PHVS is in one of them and how their past PHVS trades turned out.
PHVS News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PHVS in an article yet. Here's the latest on the wider market.
About Pharvaris N.V.
Pharvaris is a pharmaceutical company based in Leiden that is developing treatments for hereditary angioedema, a rare condition that causes episodes of severe swelling. Its product candidates, including IR and XR, are still in clinical development and have not yet received marketing approval. If approved, they would be sold to patients and physicians, with insurers and other payors deciding how much coverage to provide. The company intends them to be used alongside or in place of existing therapies.
- Headquarters
- Leiden


